CCMB to assess Ayurveda formulations' efficacy against coronavirus

Standardised Ayurveda formulations provided by AVS in Kottakkal would be tested on the lab-grown coronavirus in the cell culture system, the premier research institute here said on Friday

Ayush ministry to observe National Ayurveda Day tomorrow
Press Trust of India Hyderabad
2 min read Last Updated : Jan 01 2021 | 7:41 PM IST

Ayurveda formulations would be

tested on lab-grown strains of coronavirus by the CSIR-Centre for Cellular and Molecular Biology (CCMB) here to ascertain their anti-viral efficacy in the fight against the pathogen, under a pact with Kerala-based Arya Vaidya Sala (AVS).

Standardised Ayurveda formulations provided by AVS in Kottakkal would be tested on the lab-grown coronavirus in the cell culture system, the premier research institute here said on Friday.

"If it yields tangible results, the project will lead to a major progress in pharmaceutical industry in India," CCMB Director Rakesh Mishra said.

While the country possessed a lot of ancient wisdom, it has lacked defined regulatory protocols for testing the efficacy of formulations that were based on classical texts, he said.

In the ongoing fight against the coronavirus, it has become imperative to rigorously test the different treatment possibilities before they were used by the public, he said.

"At CCMB, we have established an efficacy testing facility for drugs and devices by using the lab-grown coronavirus.This can be used for testing the antiviral efficacy of Ayurvedic formulations too," Mishra said.

The AVS was joining hands with CCMB with the clear objective of attempting to validate classical knowledge of Ayurveda with the aid of modern science, AVS Senior Scientist C T Sulaiman said.

"We are hopeful that findings of this study will yield useful therapeutic support in the current situation. The chemical evaluation of the selected formulations showed presence of potent molecules, and they will be investigated further," he said.

AVS is a 118-years old charitable institution engaged in the practice and propagation of Ayurveda. It manufactured more than 500 formulations, the release said.

The CCMB, a premier life science research institute, has been testing, sequencing and growing coronavirus strains in its labs for various study purposes.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusAyurvedaCSIR

First Published: Jan 01 2021 | 7:19 PM IST

Next Story